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Abstract
Background: We present our 9-year consecutive case series of skull base chordomas and chondrosarcomas from a
UK tertiary referral centre, discussing treatments offered and outcomes. This was carried out to improve
understanding around current treatment and to better inform the management of future patients.
Methods: Consecutive case series over a 9-year period (2007–2016). Retrospective data analysis from the electronic
skull base multidisciplinary team database and the digital patient records at a UK tertiary referral centre
Results: Twenty-four patients were identified (11 chordomas, 13 chondrosarcomas, mean age 52). Nineteen had
proton beam therapy (PBT) postoperatively; two had intensity-modulated radiotherapy; two had no further
treatment. One patient was lost to follow-up. All chordomas were resected via a transnasal endoscopic approach.
Of the 19 patients undergoing resection with PBT, 13 were disease free at latest follow-up, and six patients had
local recurrence, of which two died (mean follow up 7.4 years). Of the three patients treated with surgery then
IMRT/TomoTherapy, one died 4 years post-treatment, and the other two are alive after 4 and 5 years of follow-up
respectively. Of the two patients treated with surgery alone, one was lost to follow-up, and the other is alive after
more than 8 years. Chondrosarcoma 5-year survival was 91.6%, and chordoma 4-year survival was 75%.
Conclusion: Skull base chordomas and chondrosarcomas can be challenging to resect, and most cases require
adjuvant therapy to achieve control. Where complete resection is not possible, it is critical to undertake sufficient
resection to permit high-dose radiation.
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Background
Chordomas and chondrosarcomas are rare bony tu-
mours of the skull base with a combined annual inci-
dence of approximately 1/100,000 [1] and a peak
incidence in the fourth to sixth decades of life [2, 3].
Despite differences in origin and prognosis, their similar
anatomical locations, clinical presentation and
radiological findings often lead the two conditions to be
considered together [4]. Chordomas arise from the rem-
nants of the primitive notochord at the spheno-occipital
synchondrosis, in comparison to chondrosarcomas
which arise from mesenchymal cells or the embryonic
rest of the cartilaginous matrix of the cranium [4].
Histological distinction can be made with immunohisto-
chemistry as chordoma is positive for epithelial markers
cytokeratin and epithelial membrane antigen (EMA),
whilst chondrosarcomas are negative for both [5]. Radio-
logically, chordomas tend to be centred on the clivus [6],
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with chondrosarcomas typically centred on the petro-
occipital fissure [5]. Diffusion-weighted MRI may aid
diagnosis [7]. Both tumours tend to be locally invasive,
and, given their proximity to the important structures of
the skull base, they can present a serious management
challenge.
Due to their rarity and the limitations of the published
literature to case series, detailed risk stratification and
prognostic data are not available. However, prognosis is
reasonable with 5-year survival of 65% for chordomas
and 81.8% for chondrosarcomas [8]. Surgery is the main
treatment modality with a number of studies suggesting
that maximising resection reduces risk of recurrence and
improves survival [9]. Complete resection is challenging
due to the locally aggressive nature of these tumours
and the close proximity to important skull base struc-
tures. Adjuvant post-operative radiotherapy is usually
administered, with a further reduction in recurrence [10,
11]. This may take the form of fractionated high-dose
photon therapy [12], proton beam therapy (PBT) [13] or
hypofractionated stereotactic [14] modalities.
We are able to present our 9-year consecutive case
series of skull base chordomas and chondrosarcomas
from a UK tertiary referral centre, discussing the treat-
ments offered and outcomes, including survival, recur-
rence and radiotherapy complications. As far as we are
aware, our case series includes the largest number of UK
skull base chordomas and chondrosarcomas managed
surgically via a transnasal endoscopic approach. This
analysis was carried out to improve understanding
around current treatment options and to better inform
the management of future patients.
Methods
Consecutive case series of all skull base chordomas and
chondrosarcomas managed at a tertiary referral centre in
the UK, over a 9-year period (2007–2016). Analysis was
performed retrospectively by review of the electronic
skull base multidisciplinary team (MDT) database and
the digital patient record system at our centre. The
above time period covers when the patients were dis-
cussed at MDT. Data was extracted by a single author
(JM) and entered into a spreadsheet for analysis. Where
gaps in the data were identified, further information was
sought through contact with the clinician in charge of
that patient’s care. This included an ENT surgeon, a
neurosurgeon and a consultant oncologist. Data ex-
tracted is summarised in Table 1.
Results
A total of 24 patients were identified (11 chordomas, 13
chondrosarcomas) with a mean age of 52 years (range
21–91). All patients underwent surgical resection, and
seven patients required more than one operation,
excluding initial biopsy. During this period, all patients
were considered for adjuvant radiation including using
proton beam therapy (PBT) via the National Health Ser-
vice programme accessing treatment abroad. All but two
patients had adjuvant radiotherapy (19 had PBT, two
had intensity modulate radiotherapy (IMRT) using
TomoTherapy locally and one patient moved abroad for
adjuvant therapy but no further treatment details were
available). Results have been divided into chordomas
and chondrosarcomas below.
Chordomas
Eleven patients were identified with a mean age of 53
years (range 23–81). All chordoma patients underwent
surgical resection via a transnasal endoscopic approach.
Four patients required more than one operation, exclud-
ing initial biopsy. Nine patients went on to have adju-
vant PBT, and one patient had IMRT. Five patients
treated with proton therapy had confirmed radiological
recurrence of their chordoma, all five of which were
local. The first of these patients underwent stereotactic
radiosurgery 3 years after her initial treatment and re-
mains alive 5 years after this; however, she now has fur-
ther disease progression. The second patient relapsed 4
years after initial treatment. This was treated with a cra-
niotomy and further resection without adjuvant radio-
therapy, and the patient is now alive and well 4 years
later. The third patient underwent further surgical resec-
tion and received adjuvant afatinib; they remain alive but
have further disease progression. The fourth patient
underwent further surgery and remains stable, despite
residual disease. The final patient relapsed 3 years after
initial treatment and died within a month of diagnosis
having had no further treatment. The patient treated
with surgery and IMRT did not relapse but died of a
cause unrelated to their chordoma 4 years post treat-
ment. Mean duration of follow-up following last treat-
ment was more than 7 years. One patient had moved
abroad for adjuvant radiotherapy, and no further treat-
ment details were available. Of the eight patients with at
least 4 years follow-up there were two mortalities giving




Adjuvant radiotherapy (PBT or TomoTherapy)
PBT dose
G3/4 toxicity (as per Common Terminology Criteria for Adverse Events
(CTCAE, v4) [13]
Local recurrence/pattern of relapse
Survival
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a 4-year survival rate of 75%. Chordoma patient treat-
ments and outcomes are summarised in Table 2.
Chondrosarcomas
Thirteen patients were identified with a mean age of 50
years (range 21–91). All 13 patients underwent surgical
resection, and seven patients required more than one
operation, excluding initial biopsy. Ten patients went on
to have adjuvant PBT, and two patients had IMRT. Only
one patient had disease recurrence following PBT, which
was at the margin of the PBT field. This patient had ini-
tially been treated with surgical debulking alone with
proton therapy as adjuvant treatment to a second
debulking 3 years after the first. He underwent a third
debulking 3 years after this. The patient ultimately died
10 years after initial diagnosis and treatment of compli-
cations relating to disease and treatment. One of the two
patients treated with surgery and TomoTherapy devel-
oped local recurrence 10 years later which was treated
with endoscopic resection and remains alive and disease
free 5 years after this. The patient that did not develop
recurrence is alive and well 9 years post treatment. One
patient had no adjuvant radiotherapy. They were an eld-
erly patient that underwent radical surgery but was felt
to be too frail to undergo radiotherapy, following MDT
discussion. Despite residual disease, this patient is func-
tioning well 6 years on from surgery. Of the 12 patients
with at least 5 years follow-up, there was one mortality
giving a 5-year survival rate of 91.6%. Chondrosarcoma
patient treatments and outcomes are summarised in
Table 3.
Complications
One patient’s surgical resection for chordoma was com-
plicated by recurrent post-operative infections and sub-
sequent haemorrhage leading to CVA, requiring a
decompressive craniotomy and shunt insertion for
hydrocephalus. A further patient required repair of a
CSF leak at a second procedure 6 weeks after initial sur-
gery when further residual chordoma was resected. Late
Table 2 Treatment and outcome summary for chordoma patients
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radiation toxicity was carotid artery stenosis leading to
significant permanent disability (1) and temporal lobe
necrosis (1) following PBT for the chordoma cohort. For
the chondrosarcoma cohort, late radiation toxicity was
temporal lobe necrosis (2), one associated with epilepsy,
and osteoradionecrosis (1) in patients receiving PBT.
Three patients developed either new or worsening of
pre-treatment cranial nerve palsies.
Discussion
We present our 9-year consecutive case series of skull
base chordomas and chondrosarcomas from a UK ter-
tiary referral centre. As far as we are aware, our case
series includes the largest number of UK skull base
chordomas and chondrosarcomas managed surgically via
a transnasal endoscopic approach. Choi et al. [3] have
published a larger case series which includes 97 patients
with chordomas of the craniocervical junction, between
two centres in the UK and Germany (1982–2007); how-
ever, most of their patients underwent resection via a
transoral or extended transoral approach, with no endo-
scopic cases. They do not comment on the use of adju-
vant radiotherapy. In terms of surgical planning, they
advocate radical resection early to improve outcomes.
They also acknowledge the unique challenges associated
with such tumours, both in terms of biology and ana-
tomical location, and as such, we agree with their rec-
ommendation that these tumours should be managed at
specialised centres via the skull base multidisciplinary
team. They report a 5-year survival of 55%, compared to
77.8% in our series, albeit with a much larger cohort.
Chordomas have a tendency to arise from the middle
and upper third of the clivus, an area that can be diffi-
cult to access surgically and one that lies in immediate
proximity to critical neurovascular structures such as the
carotid artery, brainstem and lower cranial nerves. All of
our chordomas were managed using an expanded endo-
scopic endonasal approach. This technique is well estab-
lished [15, 16] and utilises the nasal airway as a direct
route to the skull base, with the endoscope providing
narrow corridor access. The magnification improves
visualization, allowing accurate dissection of the
tumour and facilitating maximal resection, a principle
central to the management of such tumours. This is
enhanced by the use of ultra-high-definition monitors.
The use of various rigid endoscopes, ranging from 0
Table 3 Treatment and outcome summary for chondrosarcoma patients
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to 70°, further improves exposure for the operating
surgeon.
Surgical complication rates in this study were relatively
low in the context of these disease processes. Our CSF
leak rate of 4.2% (1 patient from 24) is comparable to
the 6.2% CSF leak rate reported by Choi et al. [3]; how-
ever, this is unlikely to reach statistical significance given
the small number of patients. Other complications were
rare, and anecdote suggests morbidity is more likely to
be associated with adjuvant radiotherapy.
It is well established that complete resection of skull
base chordomas and chondrosarcomas is difficult, and,
even in cases with good macroscopic clearance, there
may be microscopic tumour cells left behind. This is
demonstrated by the high recurrence rate in our series,
particularly in the chordoma cohort, and this is consist-
ent with current literature [17]. As a result, many pa-
tients can be offered higher dose adjuvant radiotherapy
which provided the best chance of local control. Excel-
lent local control rates with PBT are reported in the lit-
erature [18]. Historically, the main advantage of using
PBT over conventional photon therapy around the skull
base was the ability to deliver a higher dose of radiation
close to critical radiosensitive organs. However, the pre-
cise advantage over modern photon techniques remains
uncertain. Regardless, it is important that surgical plan-
ning takes into account the ability to deliver high-dose
radiation post resection.
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